|
Nipocalimab Clinical Trials
5 actively recruiting trials across 5 locations
Also known as: JNJ-80202135, JNJ-80202135, JNJ-86507083, M281, JNJ-80202135, M281, JNJ-86507083, M281/JNJ-80202135
Pipeline
Phase 3: 4Phase 2/3: 1
Top Sponsors
- Janssen Research & Development, LLC5
Indications
- Myasthenia Gravis3
- Cancer3
- Sjogrens Syndrome1
- Lupus Erythematosus, Systemic1
- Lupus1
Paradise Valley, Arizona1 trial
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Neuromuscular Research Center and Clinic
Phase 3
Phoenix, Arizona1 trial
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phoenix Children's Hospital
Phase 2/3
Chula Vista, California1 trial
Nipocalimab in Moderate to Severe Sjogren's Disease
Advanced Clinical Research Center
Phase 3
La Palma, California1 trial
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Advanced Medical Research
Phase 3
Farmington, Connecticut1 trial
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
University of Connecticut
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.